Short answer. If someone says the new HHS policy covers what they are offering, ask them to match the product to the policy. The policy is public [1][2]. As of Oct 29, 2026.

Sommar Club does not prescribe or sell these six. These questions are for education. They are not a green light.

Ask these

1. Which of the six is it, and is the form the acetate, or semax free base? Nicknames do not count [2].

2. Which route is on the label, and is that route in Appendix B for that peptide? KPV's sentence is topical and oral. Semax's is intranasal. Epitalon's injectable sentence says intermittent courses and does not print a schedule [2].

3. Who compounded it: a state-licensed pharmacy, a federal facility, or a licensed physician? What is the pharmacy's name and state [1]?

4. Is there a patient-specific prescription, and did a clinician review your history [2]?

5. Is there one active ingredient, or a blend [2]?

6. Can they show the original manufacturer's FDA registration and the certificate of analysis for this batch [2]?

7. Does the label say "This is a compounded drug product. Not for resale." And does it say how to report a problem [2]?

8. What happens if HHS revises the policy? The notice says it can [1].

One no, and the product is not the situation the policy describes.

Then ask a clinician something the policy cannot answer

What problem are we treating, and what options have human evidence for that problem? What would we be watching for? The policy does not establish that any of the six works [1]. Do not delay care that already exists while you collect certificates.

Private medical details belong with a clinician or in a patient portal, not in a public comment.

FAQ

Is a yes to all eight a recommendation to start? No. It means the seller's story matches the policy's conditions more closely. A clinician still decides whether a prescription is appropriate. Compounded drugs are not FDA-approved [1].

Sources

1. HHS notice, FR Doc. 2026-22192, filed Oct 28, 2026. https://public-inspection.federalregister.gov/2026-22192.pdf

2. HHS policy, conditions and Appendix B. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf

Education only. Not medical or legal advice. As of Oct 29, 2026.